196 related articles for article (PubMed ID: 28616249)
21. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome.
Ilges DT; Dermody ML; Blankenship C; Mansfield V; Van Tuyl JS
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):611-618. PubMed ID: 34138673
[TBL] [Abstract][Full Text] [Related]
22. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
[TBL] [Abstract][Full Text] [Related]
23. Association of Albuminuria Levels With the Prescription of Renin-Angiotensin System Blockade.
Qiao Y; Shin JI; Chen TK; Sang Y; Coresh J; Vassalotti JA; Chang AR; Grams ME
Hypertension; 2020 Dec; 76(6):1762-1768. PubMed ID: 32981368
[TBL] [Abstract][Full Text] [Related]
24. Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.
Qiao Y; Shin JI; Sang Y; Inker LA; Secora A; Luo S; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
Mayo Clin Proc; 2019 Nov; 94(11):2220-2229. PubMed ID: 31619367
[TBL] [Abstract][Full Text] [Related]
25. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
[TBL] [Abstract][Full Text] [Related]
26. Laboratory monitoring to reduce adverse drug-related events: a mixed methods study.
Harrison TN; Reynolds K; Hahn EE; Munoz-Plaza CE; Yi DK; Fischer H; Luong TQ; Sim JJ; Brettler J; Handler J; Mittman BS; Singh H; Kanter MH; Danforth KN
J Manag Care Spec Pharm; 2022 Jan; 28(1):16-25. PubMed ID: 34949121
[No Abstract] [Full Text] [Related]
27. A Population-Based Analysis of Quality Indicators in CKD.
Manns L; Scott-Douglas N; Tonelli M; Weaver R; Tam-Tham H; Chong C; Hemmelgarn B
Clin J Am Soc Nephrol; 2017 May; 12(5):727-733. PubMed ID: 28377473
[TBL] [Abstract][Full Text] [Related]
28. Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity.
Tisminetzky M; Gurwitz JH; Tabada G; Reynolds K; Fortmann SP; Garcia E; Pham T; Goldberg R; Go AS
Am J Med; 2022 Dec; 135(12):1468-1477. PubMed ID: 36058306
[TBL] [Abstract][Full Text] [Related]
29. Resistive index as a predictor of acute kidney injury caused by an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker in chronic kidney disease patients.
Kim ES; Kim HJ; Kim YJ; Lee SM; Lee HJ; Cho DS; Son YK; Kim SE; Kim KH; An WS
Kidney Res Clin Pract; 2013 Dec; 32(4):158-63. PubMed ID: 26877935
[TBL] [Abstract][Full Text] [Related]
30. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the early period after kidney transplantation.
Orlić L; Mikolasević I; Sladoje-Martinović B; Bubić I; Pavletić-Persić M; Racki S
Coll Antropol; 2013 Sep; 37(3):809-14. PubMed ID: 24308221
[TBL] [Abstract][Full Text] [Related]
31. Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis.
Shah M; Jain AK; Brunelli SM; Coca SG; Devereaux PJ; James MT; Luo J; Molnar AO; Mrkobrada M; Pannu N; Parikh CR; Paterson M; Shariff S; Wald R; Walsh M; Whitlock R; Wijeysundera DN; Garg AX
BMC Nephrol; 2014 Apr; 15():53. PubMed ID: 24694072
[TBL] [Abstract][Full Text] [Related]
32. Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria.
Chu CD; Powe NR; Estrella MM; Shlipak MG; McCoy IE; Tuot DS
Mayo Clin Proc; 2022 Nov; 97(11):2099-2106. PubMed ID: 36210196
[TBL] [Abstract][Full Text] [Related]
33. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
34. Who is tested for diabetic kidney disease and who initiates treatment? The Translating Research Into Action For Diabetes (TRIAD) Study.
Johnson SL; Tierney EF; Onyemere KU; Tseng CW; Safford MM; Karter AJ; Ferrara A; Duru OK; Brown AF; Narayan KM; Thompson TJ; Herman WH
Diabetes Care; 2006 Aug; 29(8):1733-8. PubMed ID: 16873772
[TBL] [Abstract][Full Text] [Related]
35. Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries.
Maciejewski ML; Hammill BG; Qualls LG; Hastings SN; Wang V; Curtis LH
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1015-22. PubMed ID: 26991354
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
MacKinnon M; Shurraw S; Akbari A; Knoll GA; Jaffey J; Clark HD
Am J Kidney Dis; 2006 Jul; 48(1):8-20. PubMed ID: 16797382
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
[TBL] [Abstract][Full Text] [Related]
39. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
